Načítá se...
Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
BACKGROUND: The mammalian target of rapamycin (mTOR) inhibitor everolimus is used in the treatment of breast cancer, neuroendocrine tumors, and renal cancer. The approved 10 mg once-daily dose is associated with considerable adverse effects and it has been suggested that these are associated with th...
Uloženo v:
| Vydáno v: | Clin Pharmacokinet |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5904242/ https://ncbi.nlm.nih.gov/pubmed/28762135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0582-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|